MDCO Share Price

Open 53.45 Change Price %
High 53.78 1 Day -1.11 -2.08
Low 52.17 1 Week -0.58 -1.10
Close 52.22 1 Month 17.86 51.98
Volume 1180671 1 Year 18.93 56.86
52 Week High 54.01
52 Week Low 29.48
MDCO Important Levels
Resistance 2 53.71
Resistance 1 53.10
Pivot 52.72
Support 1 51.34
Support 2 50.73
NASDAQ USA Most Active Stocks
CTRP 47.59 1.13%
ADBE 119.47 -0.13%
FSLR 33.57 -8.33%
FSLR 33.57 -8.33%
CERN 55.37 0.18%
BIDU 186.01 0.21%
AAPL 137.11 0.30%
AAPL 137.11 0.30%
FB 136.12 1.79%
MASI 87.05 2.03%
More..
NASDAQ USA Top Gainers Stocks
VALV 0.05 66.67%
LOCM 0.09 50.00%
BASI 1.33 31.68%
WRES 0.09 28.57%
INAP 2.31 27.62%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
AETI 2.40 23.08%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

The Medicines Company (NASDAQ: MDCO)

MDCO Technical Analysis 5
As on 22nd Feb 2017 MDCO Share Price closed @ 52.22 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 36.73 & Strong Buy for SHORT-TERM with Stoploss of 38.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
MDCO Target for February
1st Target up-side 39.22
2nd Target up-side 41.45
3rd Target up-side 43.67
1st Target down-side 32.88
2nd Target down-side 30.65
3rd Target down-side 28.43
MDCO Other Details
Segment EQ
Market Capital 1165638144.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
MDCO Address
MDCO
N/A
Interactive Technical Analysis Chart The Medicines Company ( MDCO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on The Medicines Company
MDCO Business Profile
The Medicines Company, is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace. The Company has three marketed products: Angiomax(bivalirudin), Cleviprex (clevidipine butyrate) injectable emulsion and its ready-to-use formulation of Argatroban. It also has a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. All of its acute care generic products are injectable products. In January 2013, the Company acquired Incline Therapeutics Inc. Effective August 5, 2013, The Medicines Company acquired the entire interest of ProFibrix BV, a biotechnology company. Effective December 4, 2013, The Medicines Co acquired Rempex Pharmaceuticals Inc.